vimarsana.com

Oresansky Olivier Bricaud News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Pherecydes Pharma Announces the First International Approval of a Compassionate Treatment With Its Phages

The Swedish Medical Products Agency (SMPA) has given its approval to treat a compassionate case of osteoarticular infection of a prosthetic joint with the Company's anti-S. aureus phages Regulatory

France generalUppsala lanArthur rouillPherecydes pharmaDusan oresansky olivier bricaudSwedish medical products agencyCharles fanneau de la horieExecutive boardFrench national agencyOresansky olivier bricaud

Pherecydes Pharma Announces the Appointment of Thibaut du Fayet as Chief Operating Officer and Member of the Executive Board

Regulatory News: Pherecydes Pharma (FR0011651694 ALPHE) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections

France generalArthur rouillPherecydes pharmaDusan oresansky olivier bricaudVp corporate developmentBusiness schoolRegulatory newsExecutive boardChief operatingSenior managing directorStrategy directorStrategic marketing directorAlliances programs managementCharles fanneau de la horieChief operating officerFrench national agency

Pherecydes Pharma Granted a New Patent for Its anti-Pseudomonas aeruginosa Phages in Europe

Regulatory News: Pherecydes Pharma (FR0011651694 ALPHE) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections

United statesFrance generalHong kongArthur rouillPherecydes pharmaDusan oresansky olivier bricaudEuropean patent officeRegulatory newsCharles fanneau de la horieExecutive boardFrench national agencyOresansky olivier bricaud

Pherecydes Pharma and BIOASTER Join Forces in the Treatment of Bacteremia

Regulatory News: Pherecydes Pharma (FR0011651694 ALPHE) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections

United statesFrance generalArthur rouillPherecydes pharmaDusan oresansky olivier bricaudUs centers for diseaseTechnology research institutesTechnological research instituteInstitute for technological innovation in microbiologyRegulatory newsTechnological innovationCharles fanneau de la horieExecutive boardFrench national agencyDisease controlOresansky olivier bricaud

Pherecydes Pharma Extends Its Intellectual Property in China With a First Patent Granted for Its anti-Pseudomonas aeruginosa Phages in This Territory

Regulatory News: Pherecydes Pharma (Paris:ALPHE) (FR0011651694 ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections

United statesHong kongArthur rouillPherecydes pharmaDusan oresansky olivier bricaudRegulatory newsCharles fanneau de la horieExecutive boardFrench national agencyOresansky olivier bricaud

vimarsana © 2020. All Rights Reserved.